Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP3 | Q9NSD7 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5841942 | 0.93 | CYP2D6 (0.49) | LMNANPC1ALDH1A1L3MBTL1RXFP3 | |
| SCHEMBL5842777 | 0.84 | LMNA (0.61) | LMNANPC1ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL5843197 | 0.83 | RXFP3 (0.52) | LMNAALDH1A1L3MBTL1KMT2ARXFP3 | |
| SCHEMBL5843797 | 0.83 | NPC1 (0.48) | LMNANPC1ALDH1A1GAAL3MBTL1 | |
| SCHEMBL5843922 | 0.81 | ALDH1A1 (0.64) | LMNANPC1ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL5841681 | 0.81 | ALDH1A1 (0.47) | LMNANPC1ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL5843789 | 0.81 | ALDH1A1 (0.47) | LMNANPC1ALDH1A1GAAL3MBTL1 | |
| SCHEMBL27599370 | 0.80 | MAPT (0.69) | LMNAALDH1A1L3MBTL1KMT2ARXFP3 | |
| SCHEMBL5843044 | 0.79 | ALDH1A1 (0.50) | LMNANPC1ALDH1A1L3MBTL1KDM4E | |
| SCHEMBL5842916 | 0.78 | ALDH1A1 (0.48) | LMNANPC1ALDH1A1L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067549-B2 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | LMNA 3430/4885NPC1 4071/4885ALDH1A1 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.